{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:09:56Z","timestamp":1772820596146,"version":"3.50.1"},"reference-count":17,"publisher":"Becaris Publishing Limited","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>A decision analytic model was constructed to assess the cost\u2013effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy (O-B-O) in Chinese patients with relapsed and refractory follicular lymphoma (rrFL). O-B-O was associated with a dominant or more favorable cost\u2013effectiveness than the conventional therapies. Survival outcomes, quality of life of progression-free survival, and subsequent treatment costs for progressive disease were the main drivers of the cost\u2013effectiveness of O-B-O. The cost\u2013effectiveness proportions of O-B-O relative to conventional therapies under the recommended cost\u2013effectiveness threshold ranged from 61.0% to 99.9%. Thus, O-B-O was highly cost-effective for treating patients with rrFL in China compared with conventional therapies.<\/jats:p>","DOI":"10.57264\/cer-2023-0073","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T11:42:35Z","timestamp":1698925355000},"source":"Crossref","is-referenced-by-count":5,"title":["Cost\u2013effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma"],"prefix":"10.57264","volume":"12","author":[{"given":"Jun","family":"Ma","sequence":"first","affiliation":[{"name":"Harbin Institute of Hematology &amp; Oncology, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Harbin Institute of Hematology &amp; Oncology, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bihong","family":"Zhen","sequence":"additional","affiliation":[{"name":"Shanghai Roche Pharmaceuticals Ltd, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xia","sequence":"additional","affiliation":[{"name":"Shanghai Roche Pharmaceuticals Ltd, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianyi","family":"Gong","sequence":"additional","affiliation":[{"name":"Changsha Normin Health Technology Ltd, Changsha, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendong","family":"Chen","sequence":"additional","affiliation":[{"name":"Changsha Normin Health Technology Ltd, Changsha, China"},{"name":"Normin Health Consulting Ltd, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.beha.2017.10.005","article-title":"Transformation of follicular lymphoma \u2013 why does it happen and can it be prevented?","volume":"31","author":"Link BK","year":"2018","unstructured":"Link BK. Transformation of follicular lymphoma \u2013 why does it happen and can it be prevented? Best Pract. Res. Clin. Haematol. 31(1), 49\u201356 (2018).","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"1","key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center","volume":"13","author":"Johnson PW","year":"1995","unstructured":"Johnson PW, Rohatiner AZ, Whelan JS Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J. Clin. Oncol. 13(1), 140\u2013147 (1995).","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.V128.22.615.615","article-title":"Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: updated results of the GADOLIN study","volume":"128","author":"Cheson BD","year":"2016","unstructured":"Cheson BD, Trn\u011bn\u00fd M, Bouabdallah K Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: updated results of the GADOLIN study. Blood 128(22), 615 (2016).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1182\/blood-2019-123422","article-title":"Sustained overall survival benefit of obinutuzumab plus bendamustine followed by obinutuzumab maintenance compared with bendamustine alone in patients with rituximab-refractory indolent non-hodgkin lymphoma: final results of the Gadolin Study","volume":"134","author":"Sehn LH","year":"2019","unstructured":"Sehn LH, Trn\u011bn\u00fd M, Bouabdallah K Sustained overall survival benefit of obinutuzumab plus bendamustine followed by obinutuzumab maintenance compared with bendamustine alone in patients with rituximab-refractory indolent non-hodgkin lymphoma: final results of the Gadolin Study. Blood 134(Suppl. 1), 2822 (2019).","journal-title":"Blood"},{"issue":"6","key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12185-015-1767-3","article-title":"A Phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study","volume":"101","author":"Matsumoto K","year":"2015","unstructured":"Matsumoto K, Takayama N, Aisa Y A Phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study. Int. J. Hematol. 101(6), 554\u2013562 (2015).","journal-title":"Int. J. Hematol."},{"issue":"31","key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard JP","year":"2015","unstructured":"Leonard JP, Jung SH, Johnson J Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J. Clin. Oncol. 33(31), 3635\u20133640 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clml.2014.02.010","article-title":"Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma","volume":"14","author":"Hainsworth JD","year":"2014","unstructured":"Hainsworth JD, Greco FA, Raefsky EL Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma. Clin. Lymphoma Myeloma Leuk. 14(4), 277\u2013283 (2014).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"7","key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00277-020-04101-7","article-title":"Results of R-ESHAP as salvage therapy in refractory\/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group","volume":"99","author":"Munta\u00f1ola A","year":"2020","unstructured":"Munta\u00f1ola A, Baumann T, Caballero AC Results of R-ESHAP as salvage therapy in refractory\/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group. Ann. Hematol. 99(7), 1627\u20131634 (2020).","journal-title":"Ann. Hematol."},{"key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1756-8722-5-67","article-title":"Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-na\u00efve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial","volume":"5","author":"Zinzani PL","year":"2012","unstructured":"Zinzani PL, Khuageva NK, Wang H Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-na\u00efve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. J Hematol Oncol. 5, 67 (2012).","journal-title":"J Hematol Oncol."},{"issue":"17","key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers MH","year":"2010","unstructured":"van Oers MH, Van Glabbeke M, Giurgea L Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J. Clin. Oncol. 28(17), 2853\u20132858 (2010).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"e_1_3_6_13_2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40258-018-0401-y","article-title":"Cost\u2013effectiveness of obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance versus bendamustine alone in treatment of patients with rituximab-refractory follicular lymphoma in Norway","volume":"16","author":"Haukaas FS","year":"2018","unstructured":"Haukaas FS, Ohna A, Krivasi T. Cost\u2013effectiveness of obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance versus bendamustine alone in treatment of patients with rituximab-refractory follicular lymphoma in Norway. Appl. Health Econ. Health Policy 16(4), 569\u2013577 (2018).","journal-title":"Appl. Health Econ. Health Policy"},{"key":"e_1_3_6_14_2","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-007-7596-1","volume-title":"Self-reported population health: an international perspective based on EQ-5D.","author":"Szende A","year":"2014","unstructured":"Szende A, Janssen B, Cabases J. (Eds). Self-reported population health: an international perspective based on EQ-5D. Springer, Dordrecht, Netherlands (2014)."},{"issue":"17","key":"e_1_3_6_15_2","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","article-title":"Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies","volume":"117","author":"Alduaij W","year":"2011","unstructured":"Alduaij W, Ivanov A, Honeychurch J Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 117(17), 4519\u20134529 (2011).","journal-title":"Blood"},{"issue":"26","key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.2217\/fon-2022-0112","article-title":"Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review","volume":"18","author":"Davies A","year":"2022","unstructured":"Davies A, Kater AP, Sharman JP Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. Future Oncology. 18(26), 2943\u20132966 (2022).","journal-title":"Future Oncology."},{"issue":"3","key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.18522","article-title":"Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome","volume":"200","author":"Munta\u00f1ola A","year":"2023","unstructured":"Munta\u00f1ola A, Mozas P, Mercadal S Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome. Br. J. Haematol. 200(3), 306\u2013314 (2023).","journal-title":"Br. J. Haematol."},{"issue":"31","key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy E","year":"2019","unstructured":"Bachy E, Seymour JF, Feugier P Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J. Clin. Oncol. 37(31), 2815 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.3390\/curroncol30050352","article-title":"Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada","volume":"30","author":"Kuruvilla J","year":"2023","unstructured":"Kuruvilla J, Ewara EM, Elia-Pacitti J Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada. Current Oncology. 30(5), 4663\u20134676 (2023).","journal-title":"Current Oncology."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T11:10:06Z","timestamp":1701342606000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.57264\/cer-2023-0073"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0073","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]},"article-number":"e230073"}}